Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esben Andreas Carlsen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|March 31, 2023
Mads Fich Lønnee, Esben Andreas Carlsen, Peter Hovind
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted TherapyEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2022
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine NeoplasmsEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
EJNMMI Research|October 30, 2024
Prospective phase II trial of [<sup>68</sup>Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide TherapyAleena Azam, Sorel Kurbegovic, Esben Andreas Carlsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
Routine Use of [<sup>64</sup>Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive ScansEsben Andreas Carlsen, Mathias Loft, Camilla Bardram Johnbeck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2021
Semiautomatic Tumor Delineation for Evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor VolumeEsben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, et al.
Diagnostics (Basel, Switzerland)|November 14, 2023
Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II TrialMads Lawaetz, Anders Christensen, Karina Juhl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 2020
<sup>64</sup>Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine NeoplasmsEsben Andreas Carlsen, Camilla Bardram Johnbeck, Tina Binderup, et al.
Diagnostics (Basel, Switzerland)|April 23, 2022
First-in-Human Study of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET for Integrin α<sub>v</sub>β<sub>3</sub> Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging AbilityMalene Martini Clausen, Esben Andreas Carlsen, Camilla Christensen, et al.
EJNMMI Research|May 28, 2022
A convolutional neural network for total tumor segmentation in [<sup>64</sup>Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasmsEsben Andreas Carlsen, Kristian Lindholm, Amalie Hindsholm, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|March 31, 2023
Mads Fich Lønnee, Esben Andreas Carlsen, Peter Hovind
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted TherapyEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2022
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine NeoplasmsEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
EJNMMI Research|October 30, 2024
Prospective phase II trial of [<sup>68</sup>Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide TherapyAleena Azam, Sorel Kurbegovic, Esben Andreas Carlsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
Routine Use of [<sup>64</sup>Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive ScansEsben Andreas Carlsen, Mathias Loft, Camilla Bardram Johnbeck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2021
Semiautomatic Tumor Delineation for Evaluation of <sup>64</sup>Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor VolumeEsben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, et al.
Diagnostics (Basel, Switzerland)|November 14, 2023
Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II TrialMads Lawaetz, Anders Christensen, Karina Juhl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 2020
<sup>64</sup>Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine NeoplasmsEsben Andreas Carlsen, Camilla Bardram Johnbeck, Tina Binderup, et al.
Diagnostics (Basel, Switzerland)|April 23, 2022
First-in-Human Study of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET for Integrin α<sub>v</sub>β<sub>3</sub> Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging AbilityMalene Martini Clausen, Esben Andreas Carlsen, Camilla Christensen, et al.
EJNMMI Research|May 28, 2022
A convolutional neural network for total tumor segmentation in [<sup>64</sup>Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasmsEsben Andreas Carlsen, Kristian Lindholm, Amalie Hindsholm, et al.
Pageof 2